|
|
|
Insider
Information: |
Labrucherie Gil M |
Relationship: |
Chief Financial Officer |
City: |
San Carlos |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
319,155 |
|
Indirect Shares
|
94,335 |
|
|
Direct
Value |
$576,586 |
|
|
Indirect Value
|
$320,380 |
|
|
Total
Shares |
413,490 |
|
|
Total
Value |
$896,965 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
6
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-6.0
|
Percentage
Gain/Loss : |
0.0%
|
-181.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Nektar Therapeutics |
NKTR |
SVP, COO & CFO |
2022-05-16 |
312,905 |
2008-11-14 |
0 |
Premium* |
|
Rezolute, Inc |
RZLT |
Director |
2022-05-04 |
0 |
2022-05-04 |
53,572 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
Chief Financial Officer |
2023-10-04 |
6,250 |
2023-10-04 |
40,763 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
104 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2016-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
34,421 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2016-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
71,629 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2017-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
83,414 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
103,216 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
121,266 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & Chief Financial Officer |
|
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
135,294 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2019-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
227,872 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2019-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,150 |
259,159 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
266,973 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2021-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,150 |
280,831 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2021-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
52,950 |
309,182 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP, COO & CFO |
|
2022-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
330,353 |
0 |
- |
|
SLRN |
Acelyrin, Inc. |
Chief Financial Officer |
|
2023-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
40,763 |
40,763 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-03 |
4 |
AS |
$13.78 |
$136,422 |
D/D |
(9,900) |
3,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-24 |
4 |
AS |
$15.04 |
$157,920 |
D/D |
(10,500) |
3,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-11-28 |
4 |
AS |
$17.02 |
$1,531,800 |
D/D |
(90,000) |
4,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2014-12-01 |
4 |
AS |
$17.00 |
$510,000 |
D/D |
(30,000) |
4,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-07-14 |
4 |
AS |
$11.78 |
$392,675 |
D/D |
(33,334) |
4,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-08-13 |
4 |
AS |
$10.89 |
$362,996 |
D/D |
(33,333) |
4,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-09-23 |
4 |
AS |
$13.04 |
$586,787 |
D/D |
(44,999) |
4,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-10-06 |
4 |
AS |
$10.99 |
$494,550 |
D/D |
(45,000) |
4,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-11-11 |
4 |
AS |
$13.52 |
$608,400 |
D/D |
(45,000) |
4,751 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2015-12-03 |
4 |
AS |
$15.87 |
$714,166 |
D/D |
(45,001) |
5,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2016-01-19 |
4 |
AS |
$14.12 |
$164,738 |
D/D |
(11,667) |
5,251 |
0 |
- |
|
NKTR |
Nektar Therapeutics |
SVP & General Counsel |
|
2016-02-10 |
4 |
AS |
$11.49 |
$134,042 |
D/D |
(11,666) |
5,251 |
0 |
- |
|
104 Records found
|
|
Page 1 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|